Shamburg News · 8-K filed Oct 28, 2026, 8:03 AM EDT
Benitec Announces Positive Interim Phase 1b/2a Results for High Dose BB-301
BNTC · Benitec Biopharma Inc.
- Reg FD disclosure
- Other event
- Materiality: medium
Benitec Biopharma Inc. announced positive interim Phase 1b/2a results for high dose BB-301 and continued durable improvements for low dose BB-301 in OPMD-related dysphagia, in a press release furnished as Exhibit 99.1 under Item 7.01. The company reported that 100% of patients treated across both doses are formal Responders, and that no serious adverse events have occurred in any treated patient to date. Cohort 2 (high dose) showed greater relative improvements at the 3-month time-point than Cohort 1 (low dose) in throat emptying and functional swallowing capacity.
Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001193125-26-435159.
Written from the filing by Shamburg Markets. Figures are as reported by the company.